Screener
Tango Therapeutics TNGX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Deferred revenue | — | (5,392) |
| Net cash used in operating activities | (44,360) | (41,697) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | 2 | (51) |
| Sales and maturities of marketable securities | 64,045 | 77,812 |
| Purchases of marketable securities | (54,412) | (47,164) |
| Net cash provided by investing activities | 9,635 | 30,597 |
| Cash flows from financing activities |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's capex?
- Tango Therapeutics (TNGX) reported capex of -$2K in Q1 2026.
- How has Tango Therapeutics's capex changed year-over-year?
- Tango Therapeutics's capex decreased by 103.9% year-over-year, from $51K to -$2K.
- What is the long-term trend for Tango Therapeutics's capex?
- Over 4 years (2021 to 2025), Tango Therapeutics's capex has grown at a -13.1% compound annual growth rate (CAGR), from $1.84M to $1.05M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Tango Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude